The European Medicines Agency approves two relevant vaccines for poultry farming

Published 2024년 4월 19일

Tridge summary

During its meeting from April 16 to 18, the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) approved two new vaccines, Innovax-ND-H5 for protecting chicks against the H5 type of highly pathogenic avian influenza (HPAI), and RESPIVAC TRT for immunizing chickens against virulent avian metapneumovirus. The committee also introduced a Manual for Member States focused on enhancing the quality of data management for antimicrobial sales and usage, initiated a public consultation on a draft concept paper concerning the safety of nanoparticles in veterinary medicinal products, and confirmed C. Bergman as the chair of the Veterinary Safety Task Force for an additional three years.

Disclaimer:The above summary was generated by Tridge's proprietary AI model for informational purposes.

Original content

The Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) met from 16 to 18 April to address a series of issues. At that meeting, the CVMP adopted by consensus a positive opinion for a marketing authorization application for an effective vaccine against currently circulating strains of highly pathogenic avian influenza (HPAI). This is Innovax-ND-H5 (Turkey herpesvirus, strain HVT-ND-H5 (cell-associated), which expresses the Newcastle disease virus fusion protein gene and the Newcastle disease virus hemagglutinin gene. avian influenza subtype H5, live), from Msd Animal Health, a new vaccine for the active immunization of day-old chicks or 18- to 19-day-old embryonated hen eggs to reduce mortality, clinical signs and virus shedding due to to infection by the HPAI virus type H5. Additionally, the committee adopted by consensus a positive opinion for Hipra Laboratories' marketing authorization application for RESPIVAC TRT (turkey rhinotracheitis ...

Source: Animalshealth